Other
The fifth Affiliated Hospital of Guangzhou Medcial University
Total Trials
2
Recruiting
2
Active
2
Completed
0
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Low Risk
Score: 25/100
Failure Rate
0.0%
0 terminated/withdrawn out of 2 trials
Late-Stage Pipeline
50%
1 trials in Phase 3/4
Results Transparency
0%
0 of 0 completed trials have results
Key Signals
2 recruiting
Enrollment Performance
Analytics
Phase 3
1(50.0%)
Phase 2
1(50.0%)
2Total
Phase 3(1)
Phase 2(1)
Activity Timeline
Global Presence
Loading network data...
Clinical Trials (2)
Showing 2 of 2 trials
NCT07241793Phase 2Recruiting
Phase II Study of Trastuzumab Rezetecan or in Combination With Adebrelimab in HER2-Expressing Locally Advanced or Metastatic Urothelial Carcinoma (la/mUC)
Role: collaborator
NCT06092957Phase 3Recruiting
Reduced-dose RT With/Without CCT Versus Standard CCRT for High-risk LANPC Who Achieved CR Post Induction Chemotherapy
Role: collaborator
All 2 trials loaded